top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • Apr 29
  • 1 min read

28/04/2026











AbbVie submitted an application to the FDA for upadacitinib for adults and adolescents with Severe AA (Ref)


AbbVie announced that it had submitted an application to the US FDA for RINVOQ® (upadacitinib; JAK inhibitor) for the treatment of adult and adolescent patients with severe alopecia areata (AA).


  • The submission was supported by data from the Phase 3, UP-AA/ NCT06012240 clinical program in which upadacitinib had achieved the primary endpoint of a severity of alopecia tool (SALT) score ≤ 20 at week 24, with additional efficacy observed at week 52.


  • The safety profile of upadacitinib 15 mg and 30 mg through week 52 was consistent with that observed at week 24.

















InnuCare announced that the first patient had been dosed in a Phase 3 trial of orelabrutinib for SLE (Ref)


InnoCare announced that the first patient had been dosed in a Phase 3 trial of orelabritinib (BTK inhibitor) for the treatment of systemic lupus erythematosus (SLE).


  • This was a randomized double-blind placebo-controlled multicenter Phase 3 study that evaluated the efficacy and safety of orelabrutinib in patients with SLE, with the SRI-4 response rate at week 52 as the primary endpoint.




bottom of page